Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Bleeding, as measured by: amount of blood loss; complete cessation of bleeding as assessed clinically by the investigator; time required for the control of bleeding · People of any age and either gender with post-extraction bleeding, regardless of type of teeth (anterior or posterior, mandibular or…
The review found no eligible studies for this question.
1 finding from 1 review
Discomfort associated with the procedure · People of any age and either gender with post-extraction bleeding, regardless of type of teeth (anterior or posterior, mandibular or…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tardive dyskinesia: No clinically important improvement · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes tardive dyskinesia: no clinically important improvement compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Tardive dyskinesia: deterioration in symptoms ‐ not measured · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: any · patients with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether benzodiazepines changes adverse events: any compared with phenobarbital (as active placebo) (very low certainty).
1 finding from 1 review
Improvement in PTS · patients with PTS
Rutosides may leads to lower improvement in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).
1 finding from 1 review
Deterioration in PTS · patients with PTS
Rutosides showed no clear difference in deterioration in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).
1 finding from 1 review
Adverse effects · patients with PTS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Occurrence of leg ulceration · patients with PTS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to induce remission at 10 weeks · Patients with active Crohn's disease
One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
1 finding from 1 review